ADC Therapeutics to Participate in Cowen’s 42nd Annual Health Care Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT), a biotechnology firm focused on cancer treatment, announced that CEO Chris Martin will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8 at 2:10 p.m. EST. A live webcast will be available on the company's Investors page.

The company develops next-generation antibody drug conjugates, including the FDA-approved ZYNLONTA® and others in clinical trials.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen’s virtual 42^nd Annual Health Care Conference on Tuesday, March 8^th at 2:10 p.m. EST.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005185/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023

EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

+41 (0) 43 268 3231

USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When will ADC Therapeutics' CEO participate in the Health Care Conference?

Chris Martin, CEO of ADC Therapeutics, will participate in the Cowen’s 42nd Annual Health Care Conference on March 8 at 2:10 p.m. EST.

How can I watch the ADC Therapeutics webcast?

The live webcast of ADC Therapeutics' presentation will be available on their Investors page at ir.adctherapeutics.com.

What is ZYNLONTA® and its significance?

ZYNLONTA® (loncastuximab tesirine-lpyl) is an FDA-approved ADC for treating relapsed or refractory diffuse large B-cell lymphoma.

What other developments does ADC Therapeutics have?

ADC Therapeutics is also advancing Cami (camidanlumab tesirine) and multiple other ADCs in clinical and preclinical stages.

Where is ADC Therapeutics located?

ADC Therapeutics is based in Lausanne, Switzerland, with additional operations in London, the San Francisco Bay Area, and New Jersey.